TrialDiabetes care2020

Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.

Roselle A Herring et al.PubMed ↗Publisher ↗

No numbers read from the abstract.